{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:27:44Z","timestamp":1794475664088,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41591-023-02404-6","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T12:02:07Z","timestamp":1688385727000},"page":"1710-1717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-720X","authenticated-orcid":false,"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-1061","authenticated-orcid":false,"given":"Ana Alarcon","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-4059","authenticated-orcid":false,"given":"Bianca","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-2705","authenticated-orcid":false,"given":"Andrei","family":"Holodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-5388","authenticated-orcid":false,"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2404_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2404_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2404_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 1403\u20131415 (2021).","journal-title":"Lancet Oncol."},{"key":"2404_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2404_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2404_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2404_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2404_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2404_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943\u2013947 (2018).","journal-title":"Oncologist"},{"key":"2404_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2404_CR11","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2404_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","volume":"4","author":"M Pennisi","year":"2020","unstructured":"Pennisi, M. et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 4, 676\u2013686 (2020).","journal-title":"Blood Adv."},{"key":"2404_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","volume":"28","author":"PA Riedell","year":"2022","unstructured":"Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas. Transpl. Cell Ther. 28, 669\u2013676 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"2404_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood 130, 1547 (2017).","journal-title":"Blood"},{"key":"2404_CR15","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati, P. et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137, 3272\u20133276 (2021).","journal-title":"Blood"},{"key":"2404_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690\u2013700 (2021).","journal-title":"Br. J. Haematol."},{"key":"2404_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp, M. S. et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 195, 388\u2013398 (2021).","journal-title":"Br. J. Haematol."},{"key":"2404_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"2404_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"2404_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519\u2013550 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"2404_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2404_CR22","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi, M. et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 5, 3397\u20133406 (2021).","journal-title":"Blood Adv."},{"key":"2404_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/sim.1653","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung, S. H. & Kim, K. M. On the estimation of the binomial probability in multistage clinical trials. Stat. Med. 23, 881\u2013896 (2004).","journal-title":"Stat. Med."},{"key":"2404_CR24","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.3123","volume":"27","author":"T Koyama","year":"2008","unstructured":"Koyama, T. & Chen, H. Proper inference from Simon\u2019s two-stage designs. Stat. Med. 27, 3145\u20133154 (2008).","journal-title":"Stat. Med."},{"key":"2404_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"2404_CR26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"2404_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","volume":"55","author":"EG Gutierrez","year":"1994","unstructured":"Gutierrez, E. G., Banks, W. A. & Kastin, A. J. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J. Neuroimmunol. 55, 153\u2013160 (1994).","journal-title":"J. Neuroimmunol."},{"key":"2404_CR28","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123\u20133127 (2020).","journal-title":"Blood Adv."},{"key":"2404_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","volume":"10","author":"M Wehrli","year":"2022","unstructured":"Wehrli, M. et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J. Immunother. Cancer 10, e003847 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2404_CR30","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","volume":"6","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Adv. 6, 3398\u20133403 (2022).","journal-title":"Blood Adv."},{"key":"2404_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","volume":"31","author":"J Galea","year":"2011","unstructured":"Galea, J. et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J. Cereb. Blood Flow. Metab. 31, 439\u2013447 (2011).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"2404_CR32","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2021-147454","volume":"138","author":"N Gazeau","year":"2021","unstructured":"Gazeau, N. et al. Safety and efficacy of two anakinra dose regimens for refractory CRS or Icans after CAR T-cell therapy. Blood 138, 2816 (2021).","journal-title":"Blood"},{"key":"2404_CR33","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.1200\/JCO.2021.39.15_suppl.7566","volume":"39","author":"C Oliai","year":"2021","unstructured":"Oliai, C. et al. IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome. J. Clin. Oncol. 39, 7566 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2404_CR34","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1182\/blood-2021-146927","volume":"138","author":"MJ Frigault","year":"2021","unstructured":"Frigault, M. J. et al. A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity. Blood 138, 2814 (2021).","journal-title":"Blood"},{"key":"2404_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/biostatistics\/kxx039","volume":"19","author":"Y Fong","year":"2018","unstructured":"Fong, Y., Huang, Y., Lemos, M. P. & McElrath, M. J. Rank-based two-sample tests for paired data with missing values. Biostatistics 19, 281\u2013294 (2018).","journal-title":"Biostatistics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02404-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T09:16:33Z","timestamp":1689671793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02404-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2404"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02404-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"26 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H.P. received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Inc., Curocel, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi and Takeda; received honoraria from OncLive, Physician Education Resource, and MJH Life Sciences; serves on scientific advisory board of Allogene Therapeutics and Artiva Biotherapeutics; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier and Takeda. C.S.S. has served as a paid consultant to Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite\/a Gilead Company, Celgene\/BMS, Gamida Cell, Karyopharm Therapeutics, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK; serves on DSMBs for Ono Pharmaceuticals and CRISPR Therapeutics; and has received research funds for clinical trials from Juno Therapeutics, Celgene\/BMS, Bristol Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. M.L.P. received consulting fees from BMS, Cellectar, Kite, Mustang Bio and Synthekine. G.S. received consulting fees from Amgen, BMS, Beyond Spring, and Janssen and serves on DSMB for Arcellx. P.D. received consulting fees from Kite. R.J.L. received consulting fees from Kite and Priothera. M.S. served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., Kite and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation and Amgen, Inc.; and has received honoraria from i3Health and Medscape for CME-related activity. M.-A.P. reports personal fees from Adicet, Allovir, Caribou Biosciences, Celgene, BMS, Equilium, Exevir, Karyopharm, Merck, MorphoSys, Omeros, Syncopation, VectivBio AG, Vor Biopharma, Cidara Therapeutics, Medigene, Sellas Life Sciences and NexImmune; personal fees and other support from Incyte, Kite\/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis; and other support from OrcaBio outside the submitted work. B.S. is an inventor on United States Provisional Patent Application No. US20210181179A1 \u2018Diagnosis and treatment of immunotherapy-induced neurotoxicity\u2019 filed by Memorial Sloan Kettering Cancer Center and served in a consulting or advisory role for Celgene, Janssen, Legend Biotech, Incyte, Kite\/Gilead and In8bio. A.H. is an owner\/president of fMRI Consultants, LLC. R.J.B. has licensed intellectual property to and collected royalties from BMS, Caribou and Sanofi; received research funding from BMS; is a consultant to BMS, Atara Biotherapeutics Inc., CoImmune and Triumvira; was a consultant for Gracell Biotechnologies Inc but ended employment in the past 30 months; and is a member of the scientific advisory board for CoImmune and Triumvira. I.R. reports grants from Takeda Pharmaceuticals and Atara, personal fees from Mnemo Therapeutics, Akron, the Centre for Commercialization of Cancer and Oribiotech, and other support from Bristol Myers Squibb outside the submitted work. M.S. reports grants from Atara Biotherapeutics outside the submitted work, as well as patent 8389282 issued and licensed to Juno Therapeutics, patent 11242375 issued and licensed to Atara Biotherapeutics, patent 10370452 issued, licensed and with royalties paid from Fate Therapeutics, patent 11377637 issued and licensed to Takeda Pharmaceuticals, patent 11377637 issued and licensed to Mnemo Therapeutics, and patent 11377637 issued and licensed to Minerva Biotechnologies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}